|
Contents |
|
|
|
|
|
|
|
Diagnosis
|
  
|
|
|
|
Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB.
Quantitative
volumetric analysis of conventional MRI response in recurrent glioblastoma
treated with bevacizumab.
Neuro Oncol. 2011 Apr;13(4):401-9.
Epub 2011 Feb 15.
.JPG)
Abstract |
.gif)
Related articles
|
|
|
Narang J, Jain R, Arbab AS, Mikkelsen T, Scarpace L, Rosenblum ML, Hearshen
D, Babajani-Feremi A.
Differentiating
treatment-induced necrosis from recurrent/progressive brain tumor using
nonmodel-based semiquantitative indices derived from dynamic
contrast-enhanced T1-weighted MR perfusion.
Neuro Oncol. 2011 Sep;13(9):1037-46.
Epub 2011 Jul 29.
Abstract |
Related articles
|
|
|
Rheims S, Ricard D, van den Bent M, Taillandier L, Bourg V, Désestret V,
Cartalat-Carel S, Hermier M, Monjour A, Delattre JY, Sanson M, Honnorat J,
Ducray F.
Peri-ictal
pseudoprogression in patients with brain tumor.
Neuro Oncol. 2011 Jul;13(7):775-82.
Abstract |
Related articles
|
|
|
Overall
Management
|
|
|
|
|
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR,
Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR,
Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY.
Clinical
trial end points for high-grade glioma: the evolving landscape.
Neuro Oncol. 2011
Mar;13(3):353-61. Epub 2011 Feb 9.
Abstract |
Related articles
|
|
|
Prognosis
|
|
|
|
|
Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D,
Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das
A, Friedman HS.
Response
as a predictor of survival in patients with recurrent glioblastoma treated
with bevacizumab.
Neuro Oncol. 2011 Jan;13(1):143-51.
Epub 2010 Nov 17.
Abstract | .png)
Reprint |
Related articles
|
|
|
Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM,
Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel
I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent
MJ; Dutch Society for Neuro-Oncology.
First-line
temozolomide chemotherapy in progressive low-grade astrocytomas after
radiotherapy: molecular characteristics in relation to response.
Neuro Oncol. 2011 Feb;13(2):235-41.
Epub 2010 Dec 21.
Abstract |
Related articles
|
|
|
Psychosocial
Aspects
|
|
|
|
|
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T,
Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R,
Vredenburgh J, Das A, Friedman HS.
Neurocognitive
function in patients with recurrent glioblastoma treated with bevacizumab.
Neuro Oncol. 2011 Jun;13(6):660-8.
Epub 2011 May 9.
Abstract |
Related articles
|
|
|
Weller M.
Neurocognitive
function: an emerging surrogate endpoint for neuro-oncology trials.
Neuro Oncol. 2011 Jun;13(6):565.
Abstract |
Related articles
|
|
|
Treatment
|
|
|
|
Laboratory
Investigations
|
|
|
|
|
Byer SJ, Eckert JM, Brossier NM, Clodfelder-Miller BJ, Turk AN, Carroll AJ,
Kappes JC, Zinn KR, Prasain JK, Carroll SL.
Tamoxifen
inhibits malignant peripheral nerve sheath tumor growth in an estrogen
receptor-independent manner.
Neuro Oncol. 2011 Jan;13(1):28-41.
Epub 2010 Nov 12.
Abstract |
Reprint |
Related articles
|
|
|
Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M.
Pathway
inhibition: emerging molecular targets for treating glioblastoma.
Neuro Oncol. 2011 Jun;13(6):566-79.
Abstract |
Related articles
|
|
|
Clinical
Investigations
|
|
|
|
|
Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A,
Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor
M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH;
Trabedersen Glioma Study Group.
Targeted
therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen:
results of a randomized and controlled phase IIb study.
Neuro Oncol. 2011 Jan;13(1):132-42.
Epub 2010 Oct 27.
Abstract |
Reprint |
Related articles
|
|
|
Combs SE, Debus J, Schulz-Ertner D.
Radiotherapeutic alternatives for previously irradiated recurrent
gliomas.
BMC Cancer. 2007 Aug 30;7:167.
Abstract |
Reprint |
Related articles
|
|
|
Heimberger AB, Sampson JH.
Immunotherapy
coming of age: what will it take to make it standard of care for
glioblastoma?
Neuro Oncol. 2011 Jan;13(1):3-13.
Epub 2010 Dec 10.
Abstract |
Reprint |
Related articles
|
|
|
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH,
Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA,
Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB.
Greater
chemotherapy-induced lymphopenia enhances tumor-specific immune responses
that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro Oncol. 2011
Mar;13(3):324-33. Epub 2010 Dec 10.
Abstract |
Related articles
|
|
|
Treatment
Overviews
|
|
|
|
|
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF,
Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen
PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP,
Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum
MK, Panageas KS.
International
retrospective study of over 1000 adults with anaplastic oligodendroglial
tumors.
Neuro Oncol. 2011 Jun;13(6):649-59.
Abstract |
Related articles
|
|
